Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.42 |
| ▸ | GLS | O94925 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1800444 | 0.86 | HDAC1 (0.42) | HDAC1GLSHDAC3HDAC2NCOR2 | |
| SCHEMBL1801898 | 0.86 | GLS (0.46) | HDAC1GLSHDAC3HDAC2NCOR2 | |
| SCHEMBL27761588 | 0.83 | HDAC1 (0.42) | HDAC1GLSHDAC3HDAC2NCOR2 | |
| SCHEMBL13849611 | 0.83 | TLR7 (0.42) | HDAC1GLSHDAC3HDAC2NCOR2 | |
| SCHEMBL2292448 | 0.80 | HDAC1 (0.48) | HDAC1HDAC3HDAC2NCOR2ALDH1A1 | |
| SCHEMBL3934276 | 0.78 | ALDH1A1 (0.46) | HDAC1HDAC3HDAC2NCOR2TDP1 | |
| SCHEMBL14987122 | 0.77 | GLS (0.54) | GLSSLC7A5ALDH1A1GAAGFER | |
| SCHEMBL1801093 | 0.77 | HDAC1 (0.43) | HDAC1GLSHDAC3HDAC2NCOR2 | |
| SCHEMBL1800461 | 0.76 | PTGDR2 (0.46) | ALDH1A1PTGDR2 | |
| SCHEMBL5884593 | 0.76 | HDAC1 (0.53) | HDAC1HDAC3HDAC2NCOR2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951954-B2 | Bezothiazol derivatives as Beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | HDAC1 611/4885GLS 4102/4885HDAC3 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.